Literature DB >> 10660577

HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells.

G Zauli1, P Secchiero, L Rodella, D Gibellini, P Mirandola, M Mazzoni, D Milani, D R Dowd, S Capitani, M Vitale.   

Abstract

Treatment of dopaminergic rat PC12 cells with human immunodeficiency virus, type 1 (HIV-1) Tat protein or tat cDNA inhibited the expression of tyrosine hydroxylase (TH), the rate-limiting enzyme for the dopamine biosynthetic pathway, as well as the production and release of dopamine into the culture medium. Moreover, the Tat addition to PC12 cells up-regulated the expression of the inducible cAMP early repressor (ICER), a specific member of the cAMP-responsive element modulator transcription factor family, in a cAMP-dependent manner. In turn, ICER overexpression abrogated the transcription activity of the TH promoter in PC12 cells, strongly suggesting ICER involvement in Tat-mediated inhibition of TH gene expression. In vivo injection of synthetic HIV-1 Tat protein into the striatum of healthy rats induced a subclinical Parkinson's-like disease that became manifested only when the animals were treated with amphetamine. As early as one week postinjection, the histochemical examination of the rat substantia nigra showed a reduced staining of neurons expressing TH followed by a loss of TH(+) neurons at later time points. As Tat protein can be locally released into the central nervous system by HIV-1-infected microglial cells, our findings may contribute to the explanation of the pathogenesis of the motorial abnormalities often reported in HIV-1 seropositive individuals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10660577     DOI: 10.1074/jbc.275.6.4159

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Authors:  C Scheller; G Arendt; T Nolting; C Antke; S Sopper; M Maschke; M Obermann; A Angerer; I W Husstedt; F Meisner; E Neuen-Jacob; H W Müller; P Carey; V Ter Meulen; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

2.  Evidence for developmental dopaminergic alterations in the human immunodeficiency virus-1 transgenic rat.

Authors:  Katy M Webb; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

3.  A GluN2B-Selective NMDAR Antagonist Reverses Synapse Loss and Cognitive Impairment Produced by the HIV-1 Protein Tat.

Authors:  Jonathan D Raybuck; Nicholas J Hargus; Stanley A Thayer
Journal:  J Neurosci       Date:  2017-07-17       Impact factor: 6.167

4.  Dopaminergic marker proteins in the substantia nigra of human immunodeficiency virus type 1-infected brains.

Authors:  Janelle M Silvers; Michael Y Aksenov; Marina V Aksenova; Jacob Beckley; Petra Olton; Charles F Mactutus; Rosemarie M Booze
Journal:  J Neurovirol       Date:  2006-04       Impact factor: 2.643

5.  Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity.

Authors:  Honghong Yao; Fuwang Peng; Navneet Dhillon; Shannon Callen; Sirosh Bokhari; Lisa Stehno-Bittel; S Omar Ahmad; John Q Wang; Shilpa Buch
Journal:  J Neurosci       Date:  2009-02-11       Impact factor: 6.167

6.  Novel neuroprotective GSK-3β inhibitor restricts Tat-mediated HIV-1 replication.

Authors:  Irene Guendel; Sergey Iordanskiy; Rachel Van Duyne; Kylene Kehn-Hall; Mohammed Saifuddin; Ravi Das; Elizabeth Jaworski; Gavin C Sampey; Svetlana Senina; Leonard Shultz; Aarthi Narayanan; Hao Chen; Benjamin Lepene; Chen Zeng; Fatah Kashanchi
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 7.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

Review 8.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

9.  Neurotoxicity of HIV-1 Tat protein: involvement of D1 dopamine receptor.

Authors:  Janelle M Silvers; Marina V Aksenova; Michael Y Aksenov; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurotoxicology       Date:  2007-07-22       Impact factor: 4.294

10.  Neuronal toxicity in HIV CNS disease.

Authors:  Jane Kovalevich; Dianne Langford
Journal:  Future Virol       Date:  2012-07-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.